russjcardiolРоссийский кардиологический журналRussian Journal of Cardiology1560-40712618-7620«SILICEA-POLIGRAF» LLC10.15829/1560-4071-2014-11-88-92russjcardiol-156Research ArticleЛЕКЦИИLECTUREРЕЦЕПТОРЫ, АКТИВИРУЕМЫЕ ПРОЛИФЕРАТОРАМИ ПЕРОКСИСОМ, И ИХ КОАКТИВАТОР — PGC-1α — В ФИЗИОЛОГИИ И ПАТОЛОГИИ МИОКАРДАPEROXYSOME PROLIFERATOR-ACTIVATED RECEPTORS AND THEIR COACTIVATOR — PGC-1α — IN PHYSIOLOGY AND PATHOLOGY OF MYOCARDIUMРасинМ. С.RasinM. S.

Профессор кафедры внутренней медицины №3

profrasin@gmail.comУкраинская медицинская стоматологическая академия, ПолтаваУкраинаUkraine Medical Stomatology Academy, PoltavaUkraine2014281120140118892Copyright © Расин М.С., 20142014Расин М.С.Rasin M.S.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://russjcardiol.elpub.ru/jour/article/view/156

Рецепторы, активируемые пролифераторами пероксисом (PPAR) α и β/δ управляют экспрессией генов окисления жирных кислот (ЖК), являющихся источником 70-90% АТФ в миокарде. PPARα контролирует окисление ЖК и влияет на энергетический гомеостаз миокарда, главным образом, через поставку циркулирующих ЖК из печени, а PPARγ предохраняет миокард от избытка ЖК и липотоксичности путем перераспределения потоков ЖК в адипоциты. PPARβ/δ является главным регулятором липидного обмена в мышцах, составляющих до 50% массы тела. Система PPAR/PGC-1α (главным образом, PPARα/PGC-1α) контролирует биогенез митохондрий и, таким образом, обеспечивает возможность приспособления миокарда к внезапно возникающей (стрессорной) нагрузке. Экспрессия PPARα/ PGC-1α увеличивается при физиологических формах гипертрофии миокарда: в постнатальном развитии и физической тренировке и уменьшается при патологических формах гипертрофии миокарда и сердечной недостаточности. Дисфункция регуляторной системы — PPAR/ PGC-1α может быть одним из патогенетических механизмов развития кардиомиопатий, а сигнальные пути этой системы – объектом терапевтических воздействий.

The receptors, activated by peroxysome proliferators (PPAR) α and β/δ do rule the gene expression of fatty acids (FA), that are the source of 70-90% ATP in myocardium. PPAR α controls FA oxydation and influences myocardial energy metabolism homeostasis, mostly through the supplement of circulating FA from the liver, and PPARγ prevent the excess of FA in myocardium with lipotoxicity prevented by switching the flow of FA to adipocytes. PPARβ/δ is the main regulator of lipid metabolism on muscles, that are 50% of body mass. The PPAR/PGC-1α system (mostly PPARα/PGC-1α) controls the biogenesis of mitochondria and hence makes available the possibility to adaptate myocardium for sudden (stress) exertion. Expression of PPARα/PGC-1α increases in physiologic forms of myocardial hypertrophy: in postnatal period and physical entraining, and decreases in pathological forms of myocardial hypertrophy and heart failure. Dysfunction of regulatory system PPAR/ PGC-1α might be one of the pathogenetic mechanisms of cardiomyopathy development, and signal pathways for the system the object for therapeutic interventions.

рецепторыактивируемые пролифераторами пероксисомжирные кислотыэнергетический гомеостаз миокардасердечная недостаточностьreceptorsactivated by peroxysome proliferatorsfatty acidsenergy homeostasis of myocardiumheart failureReferencesFink BN. The PPAR regulatory system in cardiac physiology and disease. Cardovascular research.-2007; 73: 269-77.Fink BN. The PPAR regulatory system in cardiac physiology and disease. Cardovascular research.-2007; 73: 269-77.Davila-Roman VG, Vedala G, Herrero P, et al. Altered myocardial fatty acid and glucose metabolism in idiopathic dilated cardiomyopathy. J Am Coll Cardiol 2002; 40: 271–7.Davila-Roman VG, Vedala G, Herrero P, et al. Altered myocardial fatty acid and glucose metabolism in idiopathic dilated cardiomyopathy. J Am Coll Cardiol 2002; 40: 271–7.Desvergne B, Wahli W. Peroxisome proliferator-activated receptors: nuclear control of metabolism. Endocr Rev 1999; 20: 649-88.Desvergne B, Wahli W. Peroxisome proliferator-activated receptors: nuclear control of metabolism. Endocr Rev 1999; 20: 649-88.Rubins HB, Robins SJ, Collins D, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med 1999; 341: 410-8.Rubins HB, Robins SJ, Collins D, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med 1999; 341: 410-8.Huss JM, Levy FH, Kelly DP. Hypoxia inhibits the peroxisome proliferator-activated receptor alpha/retinoid X receptor gene regulatory pathway in cardiac myocytes: a mechanism for O2-dependent modulation of mitochondrial fatty acid oxidation. J Biol Chem 2001; 276: 27605-12.Huss JM, Levy FH, Kelly DP. Hypoxia inhibits the peroxisome proliferator-activated receptor alpha/retinoid X receptor gene regulatory pathway in cardiac myocytes: a mechanism for O2-dependent modulation of mitochondrial fatty acid oxidation. J Biol Chem 2001; 276: 27605-12.Aasum E, Cooper M, Severson DL, et al. Effect of BM 17.0744, a PPARalpha ligand, on the metabolism of perfused hearts from control and diabetic mice. Can J Physiol Pharmacol. 2005; 83: 183-90.Aasum E, Cooper M, Severson DL, et al. Effect of BM 17.0744, a PPARalpha ligand, on the metabolism of perfused hearts from control and diabetic mice. Can J Physiol Pharmacol. 2005; 83: 183-90.Park SY, Cho YR, Finck BN, et al. Cardiac-specific overexpression of peroxisome proliferator-activated receptor-alpha causes insulin resistance in heart and liver. Diabetes2005;54: 2514-24.Park SY, Cho YR, Finck BN, et al. Cardiac-specific overexpression of peroxisome proliferator-activated receptor-alpha causes insulin resistance in heart and liver. Diabetes2005;54: 2514-24.Finck BN., Kelly DP. Peroxisome Proliferator–Activated Receptor γ Coactivator-1 (PGC-1) Regulatory Cascade in Cardiac Physiology and Disease. Circulation.-2007; 115: 2540-8.Finck BN., Kelly DP. Peroxisome Proliferator–Activated Receptor γ Coactivator-1 (PGC-1) Regulatory Cascade in Cardiac Physiology and Disease. Circulation.-2007; 115: 2540-8.Luptak I, Balschi JA, Xing Y, et al. Decreased contractile and metabolic reserve in peroxisome proliferator-activated receptor-alpha-null hearts can be rescued by increasing glucose transport and utilization. Circulation 2005; 112: 2339-46.Luptak I, Balschi JA, Xing Y, et al. Decreased contractile and metabolic reserve in peroxisome proliferator-activated receptor-alpha-null hearts can be rescued by increasing glucose transport and utilization. Circulation 2005; 112: 2339-46.Kaydashev IP. NF-kB-signaling as a basis for the development of systemic inflammation, insulin resistance, lipotoxicity, diabetes type 2 and atherosclerosis International Journal of Endocrinology 2011; 3 (35): 35-40. Russian (Кайдашев И. П. NF-kB-сигнализация как основа развития системного воспаления, инсулинорезистентности, липотоксичности, сахарного диабета 2-го типа и атеросклероза. Международный эндокринологический журнал 2011; 3(35): 35-40).Kaydashev IP. NF-kB-signaling as a basis for the development of systemic inflammation, insulin resistance, lipotoxicity, diabetes type 2 and atherosclerosis International Journal of Endocrinology 2011; 3 (35): 35-40. Russian (Кайдашев И. П. NF-kB-сигнализация как основа развития системного воспаления, инсулинорезистентности, липотоксичности, сахарного диабета 2-го типа и атеросклероза. Международный эндокринологический журнал 2011; 3(35): 35-40).Rasin OM, Kaydashev IP, Rasin MS. Molecular mechanisms of anti-inflammatory action of statins and glitazones: the role of PPAR-γ. International Journal of Endocrinology 2007; 6 (12): 71-6. Ukrainian (Расін О. М., І. П. Кайдашев, М. С. Расін. Молекулярні механізми протизапальної дії глітазонів та статинів: роль PPAR-γ. Міжнародний ендокринологічний журнал. 2007;6 (12): 71-6).Rasin OM, Kaydashev IP, Rasin MS. Molecular mechanisms of anti-inflammatory action of statins and glitazones: the role of PPAR-γ. International Journal of Endocrinology 2007; 6 (12): 71-6. Ukrainian (Расін О. М., І. П. Кайдашев, М. С. Расін. Молекулярні механізми протизапальної дії глітазонів та статинів: роль PPAR-γ. Міжнародний ендокринологічний журнал. 2007;6 (12): 71-6).Walczak R, Tontonoz P. PPARadigms and PPARadoxes: expanding roles for PPARg in the control of lipid metabolism. J Of Lipid Research.-2002; 43: 176-85.Walczak R, Tontonoz P. PPARadigms and PPARadoxes: expanding roles for PPARg in the control of lipid metabolism. J Of Lipid Research.-2002; 43: 176-85.Karagiannis E, et al. The IRIS V study: pioglitazone improves systemic chronic inflammation in patients with type 2 diabetes under daily routine conditions. Diabetes Technol Ther 2008;10(3):P. 1206-59.Karagiannis E, et al. The IRIS V study: pioglitazone improves systemic chronic inflammation in patients with type 2 diabetes under daily routine conditions. Diabetes Technol Ther 2008;10(3):P. 1206-59.Ohshima K, Mogi M, Horiuchi M. Role of Peroxisome Proliferator-Activated Receptor-γ in Vascular Inflammation. Int J Vasc Med. 2012; 2012: 508416. doi: 10.1155/2012/508416.Ohshima K, Mogi M, Horiuchi M. Role of Peroxisome Proliferator-Activated Receptor-γ in Vascular Inflammation. Int J Vasc Med. 2012; 2012: 508416. doi: 10.1155/2012/508416.Hirabara SM, Gorjão R, Vinolo MA, et al. Molecular Targets Related to Inflammation and Insulin Resistance and Potential Interventions. Journal of Biomedicine and Biotechnology Volume 2012 (2012), Article ID 379024, doi:10.1155/2012/379024 20.Hirabara SM, Gorjão R, Vinolo MA, et al. Molecular Targets Related to Inflammation and Insulin Resistance and Potential Interventions. Journal of Biomedicine and Biotechnology Volume 2012 (2012), Article ID 379024, doi:10.1155/2012/379024 20.Duan SZ, Ivashchenko CY, Russell MW, et al. Cardiomyocyte-specific knockout and agonist of peroxisome proliferator-activated receptor-gamma both induce cardiac hypertrophy in mice. Circ Res 2005; 97: 372-9.Duan SZ, Ivashchenko CY, Russell MW, et al. Cardiomyocyte-specific knockout and agonist of peroxisome proliferator-activated receptor-gamma both induce cardiac hypertrophy in mice. Circ Res 2005; 97: 372-9.Cabrero A, Jove M, Planavila A, et al. Down-regulation of acyl-CoA oxidase gene expression in heart of troglitazone-treated mice through a mechanism involving chicken ovalbumin upstream promoter transcription factor II. Mol Pharmacol 2003; 64:764-72.Cabrero A, Jove M, Planavila A, et al. Down-regulation of acyl-CoA oxidase gene expression in heart of troglitazone-treated mice through a mechanism involving chicken ovalbumin upstream promoter transcription factor II. Mol Pharmacol 2003; 64:764-72.Bishop-Bailey D, Bystrom O. Emerging roles of peroxisome proliferator-activated receptor-β/δ in inflammation. Pharmacology & Therapeutics 2009; 124: 141-50.Bishop-Bailey D, Bystrom O. Emerging roles of peroxisome proliferator-activated receptor-β/δ in inflammation. Pharmacology & Therapeutics 2009; 124: 141-50.Lee CH, Chawla A, Urbiztondo N, et al. Transcriptional repression of atherogenic inflammation: modulation byPPARdelta. Science 2003; 302(5644): 453-7.Lee CH, Chawla A, Urbiztondo N, et al. Transcriptional repression of atherogenic inflammation: modulation byPPARdelta. Science 2003; 302(5644): 453-7.Gilde AJ, van der Lee KA, Willemsen PH, et al. Peroxisome proliferator-activated receptor (PPAR) alpha and PPARbeta/delta, but not PPARgamma, modulate the expression of genes involved in cardiac lipid metabolism. Circ Res 2003;92: 518-24.Gilde AJ, van der Lee KA, Willemsen PH, et al. Peroxisome proliferator-activated receptor (PPAR) alpha and PPARbeta/delta, but not PPARgamma, modulate the expression of genes involved in cardiac lipid metabolism. Circ Res 2003;92: 518-24.Pesant M, Sueur S, Dutartre P, et al. Peroxisome proliferator-activated receptor delta (PPARdelta) activation protects H9c2 cardiomyoblasts from oxidative stress-induced apoptosis. Cardiovasc Res 2006; 69: 440-9.Pesant M, Sueur S, Dutartre P, et al. Peroxisome proliferator-activated receptor delta (PPARdelta) activation protects H9c2 cardiomyoblasts from oxidative stress-induced apoptosis. Cardiovasc Res 2006; 69: 440-9.Cheng L, Ding G, Qin Q, et al. Cardiomyocyte-restricted peroxisome proliferatoractivated receptor-delta deletion perturbs myocardial fatty acid oxidation and leads to cardiomyopathy. Nat Med 2004; 10: 1245-50.Cheng L, Ding G, Qin Q, et al. Cardiomyocyte-restricted peroxisome proliferatoractivated receptor-delta deletion perturbs myocardial fatty acid oxidation and leads to cardiomyopathy. Nat Med 2004; 10: 1245-50.Lehman JJ, Barger PM, Kovacs A, et al. Peroxisome proliferator-activated receptor gamma coactivator-1 promotes cardiac mitochondrial biogenesis. J Clin Invest 2000; 106: 847-56.Lehman JJ, Barger PM, Kovacs A, et al. Peroxisome proliferator-activated receptor gamma coactivator-1 promotes cardiac mitochondrial biogenesis. J Clin Invest 2000; 106: 847-56.Russell LK, Mansfield CM, Lehman JJ, et al. Cardiac-specific induction of the transcriptional coactivator peroxisome proliferator-activated receptor gamma coactivator-1 alpha promotes mitochondrial biogenesis and reversible cardiomyopathy in a developmental stage-dependent manner. Circ Res 2004; 94: 525-33.Russell LK, Mansfield CM, Lehman JJ, et al. Cardiac-specific induction of the transcriptional coactivator peroxisome proliferator-activated receptor gamma coactivator-1 alpha promotes mitochondrial biogenesis and reversible cardiomyopathy in a developmental stage-dependent manner. Circ Res 2004; 94: 525-33.Leone TC, Lehman JJ, Finck BN, et al. PGC-1alpha deficiency causes multi-system energy metabolic derangements: muscle dysfunction, abnormal weight control and hepatic steatosis. PLoS Biol 2005;.3: e10-e15.Leone TC, Lehman JJ, Finck BN, et al. PGC-1alpha deficiency causes multi-system energy metabolic derangements: muscle dysfunction, abnormal weight control and hepatic steatosis. PLoS Biol 2005;.3: e10-e15.van der Vusse GJ, van Bilsen M, Glatz JF. Cardiac fatty acid uptake and transport in health and disease. Cardiovasc Res 2000; 45: 279-29.van der Vusse GJ, van Bilsen M, Glatz JF. Cardiac fatty acid uptake and transport in health and disease. Cardiovasc Res 2000; 45: 279-29.Dewald O, Sharma S, Adrogue J, et al. Downregulation of peroxisome proliferatoractivated receptor-alpha gene expression in a mouse model of ischemic cardiomyopathy is dependent on reactive oxygen species and prevents lipotoxicity. Circulation 2005; 112: 407-15.Dewald O, Sharma S, Adrogue J, et al. Downregulation of peroxisome proliferatoractivated receptor-alpha gene expression in a mouse model of ischemic cardiomyopathy is dependent on reactive oxygen species and prevents lipotoxicity. Circulation 2005; 112: 407-15.Rupp H, Zarain-Herzberg A, Maisch B. The use of partial fatty acid oxidation inhibitors for metabolic therapy of angina pectoris and heart failure. Herz 2002;.27: 621-36.Rupp H, Zarain-Herzberg A, Maisch B. The use of partial fatty acid oxidation inhibitors for metabolic therapy of angina pectoris and heart failure. Herz 2002;.27: 621-36.Bao W, Jucker BM, Gu JL, et al. Activation of peroxisome proliferator-activated receptoralpha protects the heart from ischemia/reperfusion injury. Circulation 2003;108: 2393-9.Bao W, Jucker BM, Gu JL, et al. Activation of peroxisome proliferator-activated receptoralpha protects the heart from ischemia/reperfusion injury. Circulation 2003;108: 2393-9.Keech A, Simes RJ, Barter P, et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 2005. 366:1849-61.Keech A, Simes RJ, Barter P, et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 2005. 366:1849-61.Dormandy JA, Charbonnel B, Eckland DJ, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 2005;.366: 1279-89.Dormandy JA, Charbonnel B, Eckland DJ, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 2005;.366: 1279-89.

The authors declare that there are no conflicts of interest present.